JW (Cayman) Therapeutics Co Ltd
02126
Company Profile
Business description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact
No. 699 Zhong Ke Road
5F, Building B
Pudong New District
Shanghai
CHNT: +86 2150464201
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
281
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,503.80 | 6.90 | -0.08% |
| CAC 40 | 7,873.83 | 23.73 | 0.30% |
| DAX 40 | 23,638.56 | 72.02 | 0.31% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,602.92 | 2.06 | -0.02% |
| HKSE | 23,414.26 | 305.99 | 1.32% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 37,874.59 | 308.67 | -0.81% |
| NZX 50 Index | 12,809.20 | 22.46 | 0.18% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,257.90 | 11.10 | -0.13% |
| SSE Composite Index | 3,380.32 | 5.45 | 0.16% |